Cargando…

S4.5d Comparing the diagnostic performance of the commonly used eumycetoma diagnostic tests using sequencing of the internally transcribed spacer region as the gold standard

S4.5 MYCETOMA CLINICAL TRIAL ON FOSRAVUCONAZOLE TREATMENT IN EUMYCETOMA– TOP LINE RESULTS, SEPTEMBER 22, 2022, 10:30 AM - 12:00 PM: OBJECTIVES: Mycetoma is a neglected tropical implantation disease caused by 70 different infectious agents. Identifying the causative organism to the species level is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Siddig, Emmanuel, Nyuykonge, Bertrand, Mhmoud, Najwa, Abdallah, Omnia, Bahar, Mustafa, Ahmed, Eiman, Nyaoke, Borna, Zijlstra, Ed, Verbon, Annelies, Bakhiet, Sahar, Fahal, Ahmed, van de Sande, Wendy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Oral Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516265/ http://dx.doi.org/10.1093/mmy/myac072.S4.5d

Ejemplares similares

P445 Clinical evaluation of the performance of the most commonly used eumycetoma diagnostic tests using sequencing of the internally transcribed spacer region as the golden standard
por: Siddig, Emmanuel, et al.
Publicado: (2022)

S4.5c Using serum beta-glucan measurements and sequencing of the Madurella mycetomatis azole target gene to predict therapeutic outcome during azole treatment in human mycetoma
por: Nyuykonge, Bertrand, et al.
Publicado: (2022)

Epidemiological cut‐off values for itraconazole and ravuconazole for Madurella mycetomatis, the most common causative agent of mycetoma
por: Nyuykonge, Bertrand, et al.
Publicado: (2022)

Madurella mycetomatis grains within a eumycetoma lesion are clonal
por: Nyuykonge, Bertrand, et al.
Publicado: (2022)

Chaetomium atrobrunneum causing human eumycetoma: The first report
por: Mhmoud, Najwa A., et al.
Publicado: (2019)

S4.5b A randomized, double blind phase II proof-of-concept superiority trial of fosravuconazole 200 mg or 300 mg weekly dose versus itraconazole 400 mg daily, all three arms in combination with surgery, in patients with eumycetoma in Sudan—pharmacokinetic results
por: Brüggemann, Roger, et al.
Publicado: (2022)

Eumycetoma causative agents are inhibited in vitro by luliconazole, lanoconazole and ravuconazole
por: Nyuykonge, Bertrand, et al.
Publicado: (2022)

Metagenomic detection of eumycetoma causative agents from households of patients residing in two Sudanese endemic villages in White Nile State
por: Santona, Antonella, et al.
Publicado: (2022)

Eumycetoma with pulmonary dissemination an unusual complication: Case series and literature review
por: Adam, Sarah Ali Yahya, et al.
Publicado: (2022)

Broncho-pleuro-cutaneous fistula and pneumothorax: Rare challenging complications of chest wall eumycetoma
por: Saad, Eiman Siddig Ahmed, et al.
Publicado: (2017)

The Combination of Amoxicillin-Clavulanic Acid and Ketoconazole in the Treatment of Madurella mycetomatis Eumycetoma and Staphylococcus aureus Co-infection
por: Mhmoud, Najwa A., et al.
Publicado: (2014)

The development of a novel diagnostic PCR for Madurella mycetomatis using a comparative genome approach
por: Lim, Wilson, et al.
Publicado: (2020)

S4.5a A randomized, double blind phase II proof-of-concept superiority trial of fosravuconazole 200 mg or 300 mg weekly dose versus itraconazole 400 mg daily, all three arms in combination with surgery, in patients with eumycetoma in Sudan—top line results
por: Fahal, Ahmed Hassan, et al.
Publicado: (2022)

The First Case of Fusarium falciforme Eumycetoma in Sudan and an Extensive Literature Review about Treatment Worldwide
por: Siddig, Emmanuel Edwar, et al.
Publicado: (2023)

Screening the pandemic response box identified benzimidazole carbamates, Olorofim and ravuconazole as promising drug candidates for the treatment of eumycetoma
por: Lim, Wilson, et al.
Publicado: (2022)

Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim
por: Lim, Wilson, et al.
Publicado: (2020)

The Accuracy of Histopathological and Cytopathological Techniques in the Identification of the Mycetoma Causative Agents
por: Siddig, Emmanuel Edwar, et al.
Publicado: (2019)

Melanin production in coelomycetous agents of black grain eumycetoma
por: Lim, Wilson, et al.
Publicado: (2021)

Association of Eumycetoma and Schistosomiasis
por: van Hellemond, Jaap J., et al.
Publicado: (2013)

S6.5b Genomics and metagenomics of Madurella mycetomatis
por: Litvintseva, Anastasia, et al.
Publicado: (2022)

Th-1, Th-2 Cytokines Profile among Madurella mycetomatis Eumycetoma Patients
por: Nasr, Amre, et al.
Publicado: (2016)

The combination of manogepix and itraconazole is synergistic and inhibits the growth of Madurella mycetomatis in vitro but not in vivo
por: Konings, Mickey, et al.
Publicado: (2023)

The In Vitro Antifungal Activity of Sudanese Medicinal Plants against Madurella mycetomatis, the Eumycetoma Major Causative Agent
por: Elfadil, Hassabelrasoul, et al.
Publicado: (2015)

Revision of agents of black-grain eumycetoma in the order Pleosporales
por: Ahmed, S.A., et al.
Publicado: (2014)

Specific and sensitive loop-mediated isothermal amplification (LAMP) method for Madurella strains, eumycetoma filamentous fungi causative agent
por: Yoshioka, Isato, et al.
Publicado: (2023)

Mycetoma Pulmonary Secondaries from a Gluteal Eumycetoma: An Unusual Presentation
por: Mohamed, Nancy Awad, et al.
Publicado: (2016)

Madurella real-time PCR, a novel approach for eumycetoma diagnosis
por: Arastehfar, Amir, et al.
Publicado: (2020)

Rapid Identification of Black Grain Eumycetoma Causative Agents Using Rolling Circle Amplification
por: Ahmed, Sarah A., et al.
Publicado: (2014)

Merits and Pitfalls of Currently Used Diagnostic Tools in Mycetoma
por: van de Sande, Wendy W. J., et al.
Publicado: (2014)

Madurella mycetomatis causing eumycetoma medical treatment: The challenges and prospects
por: Elkheir, Lamis Y. M., et al.
Publicado: (2020)

Multiple Mycetoma Lung Secondaries from Knee Eumycetoma: An Unusual Complication
por: Mohamed, EL Samani Wadaa, et al.
Publicado: (2016)

The Role of Interleukin-1 cytokine family (IL-1β, IL-37) and interleukin-12 cytokine family (IL-12, IL-35) in eumycetoma infection pathogenesis
por: Abushouk, Amir, et al.
Publicado: (2019)

Ultrasound‐guided fine‐needle aspiration cytology significantly improved mycetoma diagnosis
por: Siddig, E.E., et al.
Publicado: (2022)

Encapsulated eumycetoma caused by Biatriosporamackinnonii
por: Arteaga, Daniela, et al.
Publicado: (2022)

MRI findings in cranial eumycetoma
por: Ahmed, Munawwar, et al.
Publicado: (2011)

An update on the development of novel antifungal agents for eumycetoma
por: Chandler, David J., et al.
Publicado: (2023)

Genomics and metagenomics of Madurella mycetomatis, a causative agent of black grain mycetoma in Sudan
por: Litvintseva, Anastasia P., et al.
Publicado: (2022)

Diagnostic implications of mycetoma derived from Madurella pseudomycetomatis isolates from Mexico
por: Nyuykonge, B., et al.
Publicado: (2020)

Visual ethnographic documentation: a novel tool for mycetoma awareness and advocacy
por: Fahal, Ahmed Hassan, et al.
Publicado: (2022)

Interleukin-17 and matrix metalloprotease-9 expression in the mycetoma granuloma
por: Siddig, Emmanuel Edwar, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hmkvvk89jov725hira1p5m75vg